Navigation Links
Watson's Generic Yaz(R) Receives FDA Approval
Date:11/29/2011

PARSIPPANY, N.J., Nov. 29, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz(R) oral contraceptive product.  Watson is currently involved in patent litigation with Bayer concerning this product. 

Yaz(R) had total U.S. sales of $173 million for the twelve months ending September 30, 2011, according to IMS Health. Watson's Vestura(TM) is indicated for the prevention of pregnancy and for the treatment of moderate acne in women at least 14 years old only if the patient desires an oral contraceptive for birth control.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
2. Mylan Launches Generic Version of Percodan® Tablets
3. Mylan Launches Generic Version of Sandostatin®
4. Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019
5. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
6. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
7. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
8. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
9. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
11. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 2014 Pressure BioSciences, Inc. (OTCQB: PBIO) ... the development and sale of high pressure-based sample ... today announced that Professor Ruedi Aebersold ... reproducible, and robust method to allow – for ... on small needle biopsy samples by mass spectrometry ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
(Date:10/26/2014)... October 26, 2014 The report "Protective ... Application - Global Trends & Forecast to 2019", defines ... and forecasting of volume consumed and value generated. The ... KT in 2014 to 6,701.3 KT by 2019, at ... Browse 91 market data tables and 22 figures spread ...
(Date:10/25/2014)... October 23, 2014 ViaDerma, ... pharmaceutical company devoted to bringing new products to ... 2015. , ViaDerma has developed an innovative, patent-pending ... rapid mass transfer of pharmaceutical active ingredients to ... provide immediate localized therapy. The transdermal delivery method ...
Breaking Biology Technology:Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... DIEGO, June 14, 2011 OncoSec Medical Inc. ... therapies to treat solid tumor cancers, announced today ... lead the clinical operations of OncoSec,s ElectroOncology therapies. ... Punit Dhillon, OncoSec,s President and CEO, said, "OncoSec ...
... Fox Chase Cancer Center , one of ... announced it has entered into an agreement with Life ... provide next-generation sequencing analysis of solid tumors.  The agreement ... Institute at Fox Chase, a facility that will foster ...
... Dendreon Corporation (Nasdaq: DNDN ) today announced that ... the Ernst & Young Entrepreneur Of The Year ® ... category. Dr. Gold has served as CEO ... last year received U.S. Food and Drug Administration approval for ...
Cached Biology Technology:OncoSec Announces Clinical Leadership Appointments 2OncoSec Announces Clinical Leadership Appointments 3OncoSec Announces Clinical Leadership Appointments 4Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation 2Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation 3Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation 4Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation 5Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 2Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 3Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 4Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 5
(Date:10/29/2014)... is open for the Society of Interventional ... 2015 is the one place where interventional ... health care professionals can come together to ... technologies being presented, discussed and tested. ... invasive, image-guided medicine, SIR 2015 will feature ...
(Date:10/29/2014)... chemicals from household and industrial products are in the ... for most of them, scientists have yet to determine ... first step toward doing that by estimating which substances ... is published in the ACS journal Environmental Science ... note that the risks to human health of any ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2MSU partners with Detroit to investigate death scenes 2
... let the bedbugs bite" is becoming an impossible dream ... resurgence of an ancient scourge that is fostering human ... potentially toxic materials. That,s the message from the cover ... News (C&EN), ACS, weekly newsmagazine. In the article, ...
... world leading publisher of scientific information products and services, ... Environment, today formalized their collaboration to publish the new ... the final quarter of 2011. This publication, supported by ... to the dynamic and impressive expansion of both environmental ...
... whale season, researchers from Hawai,i Institute of Marine Biology ... shed new light on the wintering grounds of the ... Pacific was always thought to be the main Hawaiian ... these grounds extend all the way throughout the Hawaiian ...
Cached Biology News:SCOPE and Elsevier partner to publish Environmental Development 2Researchers discover new wintering grounds for humpback whales using sound 2
... The PinPoint™ Vector Sequencing Primer is ... PinPoint™ Xa Vectors (Cat.# V2031, V2051, V2061). ... Xa site at nucleotides 325343, approximately 4050 ... region and can be used to determine ...
Medium for cryopreserving subcutaneous or omental preadipocytes...
... ultra high yield technology is fast - ... aRNA for gene array analysis ... , Kits specific for templates with ... , All kits contain SUPERaseIn ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
Biology Products: